INTRODUCTION
The pathologic outcome of infections is a direct consequence of the extent of metabolic dysfunction and damage imposed to tissues that sustain host homeostasis (Kotas and Medzhitov, 2015; Soares et al., 2014 Soares et al., , 2017 . Disease tolerance is a defense strategy that limits the pathologic outcome of infections without interfering directly with the host's pathogen load (Medzhitov et al., 2012) . This defense strategy relies on tissue damage control mechanisms that preserve the functional output of parenchymal tissues, maintaining homeostatic parameters within a dynamic range compatible with host survival (Kotas and Medzhitov, 2015; Soares et al., 2014 Soares et al., , 2017 .
Sepsis is a clinical syndrome, affecting $19 million individuals per year worldwide, characterized by a maladaptive host response with ensuing organ dysfunction. Despite tremendous efforts during the last decades, no specific therapy for sepsis exists. Increasing rates of antimicrobial resistance and lack of novel antimicrobials adds to the problem and substantiates the urgent need of innovative therapeutic options (Angus and van der Poll, 2013) .
The pathogenesis of sepsis is only partially explained by unfettered inflammation while metabolic deregulation, leading to organ dysfunction and eventually to organ failure, is increasingly recognized as an important component of this process (Angus and van der Poll, 2013) . While the mechanisms underlying the inflammatory response that characterizes the pathogenesis of sepsis are fairly well understood, those driving metabolic deregulation and multi-organ dysfunction or failure remain elusive (Kotas and Medzhitov, 2015; Soares et al., 2014) .
Systemic infections, including those leading to sepsis, are coupled to a host metabolic response restraining invading pathogens from accessing iron (Soares and Weiss, 2015) . The large majority of iron available to pathogens is contained within the prosthetic heme groups of hemoproteins, among which hemoglobin holds the largest reservoir . Upon hemolysis, extracellular hemoglobin is oxidized and releases heme (Larsen et al., 2010; Pamplona et al., 2007) , eventually leading to the accumulation of labile heme in plasma (i.e., metabolic active heme that is loosely bound to a variety of plasma molecules). Accumulation of labile heme in plasma plays a central role in the pathogenesis of sepsis (Larsen et al., 2010) . This is countered by the induction heme-catabolism by heme oxygenase-1 (HO-1), which contributes critically to the establishment of disease tolerance to sepsis (Larsen et al., 2010) . As a trade-off, however, heme catabolism by HO-1 generates labile iron that can catalyze the production of reactive oxygen species via Fenton chemistry, eventually leading to oxidative stress. This is counteracted by ferritin, a heteropolymeric protein complex encoded by the ferritin heavy/ heart chain (FTH) and light/liver (FTL) genes (Harrison and Arosio, 1996) . Ferritin is composed of 24 FTH/FTL subunits, which can store and convert $4,500 atoms of Fe 2+ into inert Fe 3+ through the ferroxidase activity of FTH (Harrison and Arosio, 1996) . The ferroxidase activity of ferritin is critical to the establishment of disease tolerance to infection in animals and plants (Deá k et al., 1999) . Here, we demonstrate that FTH establishes disease tolerance to sepsis via a mechanism that sustains the expression/activity of the liver G6Pase, a rate-limiting enzyme in the gluconeogenesis and glycogenolysis pathways (Mithieux, 1997; van Schaftingen and Gerin, 2002) . This is required to support liver glucose production in response to systemic infections so that blood glucose levels are maintained within a dynamic physiologic range compatible with host survival, hence conferring disease tolerance to sepsis.
RESULTS

FTH Is Essential to the Establishment of Disease Tolerance to Sepsis
Expression of FTH protein (Figures 1A and 1B) by liver F4/80 + macrophages and hepatocytes ( Figures 1C, S1A , and S1B), was readily induced in C57BL/6 mice subjected to cecal ligation and puncture (CLP), a well-established experimental model of polymicrobial infection. Liver Fth mRNA was only slightly induced ( Figure S1C ), consistent with post-transcriptional regulation of FTH expression (Hentze et al., 1987) .
Mx1
Cre Fth D/D mice, in which the Fth lox/lox allele was deleted in an inducible manner in the liver and hematopoietic cells (Figure assessed for aerobic and anaerobic bacteria in different organs 48 hr after CLP ( Figure 1F ). This demonstrates that FTH is required to establish disease tolerance to sepsis in mice. Figure 1H ). This suggests that FTH expression in hepatocytes, and presumably in macrophages, is required to establish disease tolerance to sepsis. When subjected to a defined polymicrobial inoculum isolated from human microbiota (peritoneal contamination and infection [PCI] ), Mx1
Cre Fth D/D mice developed clinical signs of severe disease ( Figure 1I ) and succumbed ( Figure 1J) Figure S2A ). This suggests that FTH confers disease tolerance to sepsis via a mechanism that does not involve a putative immunoregulatory effect.
The extent of organ dysfunction in Mx1
Cre Fth D/D and Fth lox/lox mice subjected to CLP was similar, as monitored for liver, muscle, and kidney by the accumulation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK), lactate dehydrogenase (LDH), and blood urea nitrogen (BUN) in plasma, respectively ( Figure S2B ), confirmed by histological analyzes ( Figure S2C ). This suggests that disease tolerance to sepsis does not rely on the well-established cytoprotective effect of FTH . Cardiovascular damage ( Figure S3A ), cardiac function (Figure S3B) , and vascular integrity ( Figure S3C ) were similar in
Mx1
Cre Fth D/D and Fth lox/lox mice subjected to CLP. This suggests that FTH is not required to prevent the development of cardiovascular dysfunction, a hallmark of sepsis (Angus and van der Poll, 2013) .
FTH Regulates Glucose Metabolism in Response to
Infection When subjected to CLP, Mx1
Cre Fth D/D mice decreased body weight ( Figure 2A ) and temperature ( Figure 2B ) more so than Fth lox/lox mice. Food intake (i.e., anorexia of infection) was similar in Mx1
Cre Fth D/D and Fth lox/lox mice ( Figure S4A ), suggesting that FTH regulates metabolic adaptation to infection rather than sickness behavior.
Blood glucose levels 24 hr after CLP were reduced to similar levels in Mx1
Cre Fth D/D and Fth lox/lox mice ( Figure 2C ). However, while within the following days blood glucose levels were partially restored in Fth lox/lox mice, this was not the case for
Mx1
Cre Fth D/D mice that went on to succumb to CLP ( Figure 2C ).
Glucose administration to Mx1
Cre Fth D/D mice, starting from 12 hr after CLP onward, restored blood glucose levels ( Figure 2D ) and survival ( Figure 2E ), as compared to vehicle-treated controls ( Figures 2D and 2E ). This was not associated with modulation of pathogen load ( Figure 2F ), suggesting that FTH establishes disease tolerance to sepsis via a mechanism that regulates glucose metabolism.
Of note, both Mx1
Cre Fth D/D and Fth lox/lox mice increased blood glucose levels in the first 6 hr following CLP ( Figure S4B ), which was also the case in sham-operated mice ( Figure S4C ). This suggests that this early metabolic response is (1) likely elicited by tissue injury, and (2) not controlled by FTH. We then asked whether extracellular accumulation of labile heme following CLP ( Figure S4D ) contributes to deregulate glucose metabolism. Heme administration to C57BL/6 mice decreased blood glucose levels ( Figure 2G ), an effect not observed in control mice receiving a synthetic protoporphyrin IX lacking iron ( Figure 2G ). In contrast to Fth lox/lox mice, heme administration to Mx1
Cre Fth D/D mice led to severe hypoglycemia ( Figure 2H ) and death ( Figure 2I ). This suggests that FTH counters the development of iron heme-driven hypoglycemia in response to polymicrobial infections. Of note, reduction of blood glucose levels in response to heme administration was preceded by a transient raise in blood glucose levels not observed in response to protoporphyrin IX ( Figure S4E ). This effect was similar in Mx1
Cre
Fth
D/D and Fth lox/lox mice ( Figure S4F ), suggesting that FTH does not regulate this early iron heme-driven hyperglycemia. Labile heme is an alarmin (Soares and Bozza, 2016) sensed by the toll-like receptor 4 (TLR4) (Figueiredo et al., 2007) . TLR4-deficient (Tlr4 À/À ) mice failed to reduce blood glucose levels in response to heme administration, as compared to wild-type Tlr4 +/+ controls ( Figure 2J ). This suggests that heme reduces blood glucose levels via a TLR4-dependent mechanism. In contrast, heme reduced blood glucose levels in mice lacking type 1 interferon (IFN) receptor (Ifnr1 À/À ), to the same extent to wild-type (Ifnr1 +/+ ) controls ( Figure 2K ). This suggests that heme reduces blood glucose levels via a type 1 IFN response-independent mechanism. The early increase in blood glucose levels observed in response to heme also occurred in Tlr4 À/À ( Figure S4G ) and Figure S4H ) mice, suggesting that neither TLR4 nor type 1 IFN response are involved in this metabolic response.
FTH Promotes Liver Gluconeogenesis in Response to
Polymicrobial Infection Administration of glucose ( Figure S4I ), glucose precursors (e.g., pyruvate [ Figure S4J ] or glucagon [ Figure S4K ]), as well as insulin ( Figure S4L ), resulted in similar transient elevation and normalization of blood glucose levels in Mx1
Cre Fth D/D and Fth lox/lox mice. Levels of insulin in plasma were similar in overnight-fasted Mx1
Cre Fth D/D and Fth lox/lox mice ( Figure S4M ) or
Mx1
Cre Fth D/D and Fth lox/lox mice subjected to CLP ( Figure S4N ).
This suggests that FTH does not regulate steady-state glucose metabolism and/or regulates insulin resistance. This does not exclude insulin resistance from regulating glucose metabolism in response to acute polymicrobial infection (Wang et al., 2016 Figure 3C ) and amino acids ( Figure S5 ) involved in the gluconeogenesis and the Krebs cycle. The data obtained was integrated into the genome scale metabolic reconstruction of mouse 
Cre Fth D/D (n = 15) mice subjected to CLP. Figure S4 . metabolism iMM1415 (Sigurdsson et al., 2010) and analyzed using a flux balance analysis approach assessing the overall capability to produce ATP (Orth et al., 2010) . Metabolomics, flux balance, and flux variability analysis (Mahadevan and Schilling, 2003) , including simulations of single gene and reaction deletion of iMM1415 (Tables S1 and S2 ) (Mahadevan and Schilling, 2003) , suggest that when subjected to CLP, Mx1
Cre Fth D/D mice shifted liver glucose metabolism toward a metabolic flux characteristic of glycolysis, in detriment of gluconeogenesis, as compared to Fth lox/lox mice ( Figure 3C ). This indicates that induction of FTH in response to polymicrobial infection sustains liver gluconeogenesis in detriment of glycolysis. This is not associated, however, with changes in the relative levels of liver glucogenic amino acids, apart from cysteine ( Figure S5 ), arguing that FTH regulates the expression and/or the activity of one or several enzymes partaking in these metabolic pathways. Figure S5 and Tables S1 and S2 .
FTH Counters Iron Heme-Driven Inhibition of Liver G6Pase
To address whether FTH regulates the expression of genes controlling liver metabolic pathways that might contribute to disease tolerance to polymicrobial sepsis we performed a microarray analysis. Eight genes were differentially expressed in the liver of Mx1 Cre Fth
versus Fth lox/lox mice subjected to CLP ( Figure 4A ; GEO: GSE92703). These included Fth1, epoxide hydrolase 1 (Ephx1), glutathione S-transferase Mu 1 (Gstm1) and 2 (Gstm2), lysine-specific demethylase hairless (Hr), natriuretic peptide receptor B (Npr2), and transferrin receptor protein 1 (Tfrc), as well as the G6Pase catalytic subunit (G6pc1) (Figure 4A) , encoding the final and ratelimiting enzyme of the gluconeogenic and glycogenolytic pathways (Mutel et al., 2011; van Schaftingen and Gerin, 2002) .
Consistent with previous observations (Deutschman et al., 1997) , liver G6pc1 mRNA ( Figure 4B ) and G6pc1 protein (Figures 4C and 4D) expression were decreased in response to CLP. This effect was exacerbated in Mx1
Cre Fth D/D versus Fth lox/lox mice ( Figures 4B-4D ), confirming the microarray data ( Figure 4A ). Expression of the solute carrier family 37 member 4, i.e., glucose-6-phosphate transporter (G6PT), another component of the G6Pase complex (van Schaftingen and Gerin, 2002 ) not included in the initial RNA microarray screen ( Figure 4E ) and hepatic G6Pase enzymatic activity ( 4E ). This suggests that FTH regulates the expression and activity of the hepatic G6Pase complex in response to polymicrobial infection. Expression of G6PC1 mRNA ( Figure 4G ) was decreased in human hepatocytic HepG2 cells exposed to heme, as compared to vehicle-treated controls, which is consistent with previous findings (Yin et al., 2007) . TNF also inhibited G6PC1 mRNA expression in HepG2 cells, an effect boosted when heme and TNF were used together ( Figure 4G ). This was confirmed for G6PC1 protein expression (Figures 4H and 4I) .
We then asked what the mechanism is by which heme and TNF suppress G6PC1. Heme and TNF repressed G6pc1 transcription as assessed in HepG2 cells transiently transfected with G6pc1-luciferase reporter ( Figure 4J ). This in keeping with a previous demonstration that heme can repress G6PC1 transcription (Yin et al., 2007) .
Heme administration to C57BL/6 mice inhibited liver G6pc1 and G6pt1 mRNA expression ( Figure 4K ), an effect exacerbated in Mx1
Cre Fth D/D versus Fth lox/lox mice receiving a lower heme dosage ( Figure 4L ). This suggests that FTH counters hemedriven inhibition of liver G6Pase in vivo.
We then asked what the mechanism is by which FTH regulates G6PC1. reporter ( Figure 4L ). Moreover, FTH countered the repression of G6pc1-luciferase reporter in response to heme and TNF (Figure 4L) . This suggests that FTH promotes G6PC1 expression via a mechanism regulating its transcription. Repression of G6PC1 protein in HepG2 cells exposed to heme and TNF was not reverted by proteasome inhibition ( Figure S6A ), as observed for the cyclin-dependent kinase inhibitor 1 p21 ( Figure S6A ). This suggests that G6PC1 protein degradation is not the mechanism by which its protein levels are reduced on heme and TNF.
Transduction of HepG2 cells with a G6PC1 recombinant adenovirus (Rec.Ad.) resulted in a robust induction of G6Pase activity, as compared to control cells not transduced or transduced with a LacZ Rec.Ad. (Figure S6B ). Heme and TNF did not inhibit G6Pase activity in HepG2 cells transduced with the G6PC1 and co-transduced or not with a LacZ or FTH Rec.Ad. (Figure S6B ) Gozzelino et al., 2012) .
Liver Gluconeogenesis Is Required to Establish Disease Tolerance to Polymicrobial Infections
To address whether liver gluconeogenesis per se is required to establish disease tolerance to polymicrobial infections, we used Alb
G6pc1
D/D mice lacking liver gluconeogenesis due to inducible and specific deletion of the G6pc1 lox/lox allele in hepatocytes ( Figure 5A ) (Mutel et al., 2011) . Alb
D/D mice subjected to CLP developed severe hypoglycemia ( Figure 5B ) and succumbed ( Figure 5C ), as compared to control G6pc1 lox/lox mice that reduced transiently blood glucose levels and survived ( Figures 5B and 5C ). Loss of body temperature ( Figure S6C ), but not body weight ( Figure S6E ), was also more pronounced in Alb 
D/D mice failed to develop transient hyperglycemia in the 6-12 hr that followed CLP, as compared to control G6pc1 lox/lox mice ( Figure S6E ).
Alb
Cre ER T2 G6pc1 D/D mice also developed severe hypoglycemia ( Figure 5D ) and succumbed ( Figure 5E ) from severe disease 
Survival ( ( Figure S6F ) when subjected to PCI, as compared to control G6pc1 lox/lox mice ( Figures 5D, 5E , and S6F Figure 5F ). With the exception of the liver, the extent of organ damage was also similar in Alb
versus G6pc1 lox/lox mice, as assessed serologically ( Figure S6G) and by histology ( Figure S6H ). This shows that liver gluconeogenesis is required to establish disease tolerance to sepsis in mice. Heme administration to Alb
severe hypoglycemia ( Figure 5G ), loss of body temperature ( Figure S6I ) and body weight ( Figure S6J ), as well as higher incidence of mortality ( Figure 5H ), as compared to control G6pc1 lox/lox mice. Transient elevation of blood glucose levels in heme-treated G6pc1 lox/lox mice was not observed in Figure S6K ). This suggests that liver G6Pase is required to counter the development of lethal hypoglycemia in response to heme. Taking into consideration that heme reduces blood glucose levels via a TLR4-dependent mechanism ( Figure 2J ), we examined whether liver G6Pase is also required to counter the pathogenic effects of a bona fide TLR4 agonist such as bacterial lipopolysaccharide (LPS). Alb
severe hypoglycemia ( Figure 5I ) and succumbed ( Figure 5J ) when subjected to a sub-lethal dosage of LPS inducing mild hypoglycemia in G6pc1 lox/lox mice ( Figures 5I and 5J ). This further supports the notion that liver glucose production is strictly required to prevent the development of lethal hypoglycemia in response to systemic TLR4 signaling. We also tested whether liver glucose production is required to counter the pathogenic effect exerted by other TLR agonists, such as polyinosinic-polycytidylic acid (Poly(I:C)) a TLR3 agonist that triggers a type 1 interferon response. In contrast to heme or LPS, Poly(I:C) administration was associated with the development of mild hypoglycemia in G6pc1 lox/lox and Alb
Cre ER T2 G6pc1 D/D mice, resulting in similar levels of mortality (Figures 5K and 5L) . This argues that host adaptive responses regulating glucose metabolism are tailored to specific inflammatory insults (Soares et al., 2017; Wang et al., 2016) .
The Ferroxidase Activity of FTH Establishes Disease Tolerance to Sepsis
We hypothesized that FTH overexpression in the liver should be sufficient to re-establish disease tolerance to sepsis. Overexpression of FTH in the liver of C57BL/6 mice, via transduction of a FTH Rec.Ad. Gozzelino et al., 2012) , was protective against a severe form of CLP, as compared to control C57BL/6 mice not transduced or transduced with a LacZ Rec.Ad. (Figure 6A ). Transduction of a mutated FTH (FTH m ) lacking ferroxidase activity was not protective against CLP ( Figure 6A ). The protective effect of FTH was not associated with modulation of pathogen load ( Figure 6B) , showing that FTH overexpression establishes disease tolerance to lethal form of polymicrobial infection via a mechanism that relies on its ferroxidase activity. Of note, FTH overexpression did not prevent the development of organ dysfunction/damage in response to CLP ( Figure S7A ), arguing that the protective mechanism of FTH does not rely on its cytoprotective effect Gozzelino et al., 2012) . We then addressed whether the ferroxidase activity of FTH regulates the expression of G6PC1 in hepatocytes. Expression of G6PC1 protein was higher in HepG2 cells transduced with FTH Rec.Ad., as compared to control HepG2 cells transduced with LacZ Rec.Ad (Figures 6C and 6D) . This was not the case for HepG2 cells transduced with the FTH m Rec.Ad. (Figures 6C  and 6D ) despite similar levels of FTH m and FTH expression (Figures 6C and 6E) . This suggests that the ferroxidase activity of FTH promotes G6PC1 protein expression in hepatocytes. We then investigated whether iron chelation by DFO promotes G6PC1 expression. Inhibition of G6PC1 mRNA expression in HepG2 cells exposed to heme plus TNF was countered by DFO ( Figure 6F) , as compared to vehicle-treated controls. This reinforces the notion that the ferroxidase activity of FTH, mimicked by DFO, promotes G6PC1 expression in hepatocytes.
Soluble Ferritin Promotes the Establishment of Disease Tolerance to Sepsis
Ferritin complexes can be secreted and presumably exert biologic effects in bystander cells (Fisher et al., 2007) . We questioned whether soluble ferritin complexes can be used pharmacologically to enforce the establishment of disease tolerance to sepsis. Administration of non-iron loaded apoferritin protected C57BL/6 mice from succumbing to severe CLP, as compared to controls receiving vehicle or bovine serum abumin (BSA) (Figure 6G) . In contrast, administration of iron-loaded ferritin was not protective ( Figure 6G ). Apoferritin and iron-loaded ferritintreated mice had similar pathogen loads, as compared to controls receiving vehicle or BSA ( Figure 6H ). Apoferritin was still protective against mortality when administered up to 6 hr after severe CLP, as compared to control mice receiving vehicle or BSA ( Figure 6I ). This suggests that apoferritin administration after the onset of infection can act therapeutically to establish disease tolerance to sepsis.
Of note, apoferritin administration did not prevent the development of liver, muscle, or kidney dysfunction/damage, as compared to controls receiving vehicle or BSA ( Figure S7B ). This argues further that the mechanism by which ferritin confers disease tolerance to sepsis does not rely on its cytoprotective effects Gozzelino et al., 2012) .
Antioxidants Restore Normoglycemia and Disease Tolerance to Sepsis
Given that the ferroxidase activity of FTH sustains G6Pase expression in hepatocytes ( Figures 6C-6E) , we asked whether a pharmacologic anti-oxidant such as the glutathione precursor N-acetylcysteine (NAC) can re-establish disease tolerance in Mx1 Figure 7D ). We then asked whether NAC modulates G6PC1 expression. Inhibition of G6PC1 mRNA expression in HepG2 cells exposed to heme and TNF was prevented by NAC, as compared to vehicle-treated controls ( Figure 7E ). This suggests that heme and TNF inhibit G6Pase via a pro-oxidant effect reverted by NAC. Of note, NAC can also inhibit the activation of nuclear factor kappa B (NF-kB), a transcription factor that represses G6PC1 expression in hepatocytes (Grempler et al., 2004) . Therefore, we cannot exclude that NAC promotes G6PC1 expression via a mechanism involving NF-kB inhibition, which is probably not dissociated from the anti-oxidant effect of NAC.
In a similar manner to NAC, the lipophilic anti-oxidant butylated hydroxyanisole (BHA) also restored blood glucose levels ( Figure 7F ) and survival ( Figure 7G manner to sustain liver G6Pase expression and glucose production, contributing to establish disease tolerance to polymicrobial infections. Finally, we asked whether anti-oxidants restore glucose metabolism in mice lacking liver glucose production. NAC administration to Alb
Cre ER T2 G6pc1 D/D mice subjected to CLP failed to restore body weight ( Figure 7I ), blood glucose levels ( Figure 7J ), or improve survival ( Figure 7K ), as compared to control vehicletreated Alb Cre ER T2 G6pc1 D/D mice. This confirms that the antioxidant activity of FTH acts upstream of G6Pase to restore blood glucose levels and establish disease tolerance to sepsis.
DISCUSSION
Host metabolic responses to systemic infections are associated with induction of hypoferremia (i.e., low levels of circulating iron concomitant with iron accumulation in macrophages and parenchyma cells) (Soares and Weiss, 2015) . While critical to limit iron availability and regulate immune-driven resistance to extracellular pathogens, hypoferremia can promote the development of oxidative damage in host parenchyma tissues (Soares and Weiss, 2015) . This pathologic effect is fueled by the accumulation of labile heme in plasma, released from extracellular hemoglobin as a byproduct of hemolysis (Larsen et al., 2010) . Presumably, for this reason, the accumulation of extracellular hemoglobin in plasma is associated with poor clinical outcome of sepsis (Adamzik et al., 2012) . Moreover, high levels of the hemoglobin scavenger haptoglobin (Janz et al., 2013) or the heme scavenger hemopexin (Janz et al., 2013; Larsen et al., 2010) in plasma are associated with a better clinical outcome of sepsis.
Heme catabolism by HO-1 is critical to prevent the pathogenic effects of labile heme and establish disease tolerance to sepsis (Larsen et al., 2010) . However, under inflammatory conditions, the intracellular iron generated via heme catabolism cannot be readily exported, owed to systemic inhibition of the iron cellular exporter ferroportin by hepcidin (Drakesmith and Prentice, 2012; Nemeth et al., 2004) . Presumably, this explains why FTH becomes essential to restrict the participation of intracellular iron in the generation of reactive oxygen species via Fenton chemistry Soares and Bozza, 2016; Soares and Weiss, 2015) and to establish of disease tolerance to sepsis (Figure 1 ). While essential to establish disease tolerance to acute infections, the induction of HO-1 (Larsen et al., 2010) and FTH ( Figures 1A-1F ) is likely associated with tradeoffs, presumably explaining why the expression of these stressresponsive genes is not constitutively high at steady state. In the case of HO-1, this has been associated with the development of insulin resistance in response to chronic metabolic inflammation (Jais et al., 2014 (Okin and Medzhitov, 2016) . However, we cannot exclude that FTH might partake in the development of insulin resistance in response to chronic metabolic inflammation. Induction of FTH expression in response to acute polymicrobial infections prevents liver metabolism from shifting toward glucose consumption, via glycolysis, in detriment of glucose production, via gluconeogenesis ( Figure 3C ). We propose that this is required to compensate for reduced nutritional glucose intake associated with anorexia of infection (Wang et al., 2016) , maintaining blood glucose levels within a dynamic physiologic range compatible with host survival (Figures 2C-2E and 5B-5F) (Hermanides et al., 2010) . The anti-oxidant effect associated with the ferroxidase activity of FTH is central to this adaptive response, preventing pro-oxidant iron-heme from inhibiting liver G6Pase (Figure 4) .
While iron can catalyze oxidative modifications in G6PC1 and G6PT1 thiol (SH) groups (Clottes and Burchell, 1998) , which represses G6Pase expression and/or activity (Witzleben and Chaffey, 1962) , this does not appear to be involved in the mechanism in which heme and TNF repress G6Pase and/or the mechanism in which FTH promotes G6Pase expression and/or activity ( Figures S6A and S6B) . Instead, heme and FTH modulate G6Pase expression via a mechanism that relies on the modulation of G6PC1 transcription ( Figures 4J and 4M) .
The relative contribution of heme-activated TLR4 signaling and iron heme-induced oxidative stress to the inhibition of liver G6Pase remains unclear. At least three mechanisms might contribute to this effect: (1) TLR4 signaling in response to heme (Figueiredo et al., 2007) , (2) unfettered free radical production via the participation of heme iron in Fenton chemistry, or (3) synergic effect of TLR4 signaling and heme iron-driven oxidative stress.
Deregulation of glucose metabolism is thought to play a central role in the development of metabolic and energetic failure associated with the pathogenesis of sepsis (Lee and Hü ttemann, 2014; Pravda, 2014) . Development of insulin resistance (Yki-Jä rvinen et al., 1989 ) is perceived as an adaptive response that counters unfettered glucose utilization by host tissues, presumably preventing the development of lethal hypoglycemia in response to acute bacterial infections (Wang et al., 2016) . Our data suggest that regulation of liver glucose production by FTH is a critical component of this metabolic response, which is required to prevent the development of lethal hypoglycemia in response to acute infection.
Consistent with the notion that the accumulation of labile heme in plasma plays a central role in the pathogenesis of sepsis (Larsen et al., 2010) , we found that labile heme is sufficient per se to reduce blood glucose levels ( Figures 2C and 2G) , an effect associated with the repression of liver G6pc1 and G6pt mRNA expression ( Figures 4H-4K) . Reduction of blood glucose levels in response to heme is TLR4-dependent ( Figure 2J ), which is consistent with previous findings showing that heme can signal via TLR4 (Figueiredo et al., 2007) , and that signaling via TLR4 in response to LPS reduces blood glucose levels and represses liver G6Pase (Raetzsch et al., 2009 both at baseline or when subjected to polymicrobial infection. A significant proportion of iron-loaded ferritin is secreted, and the physiologic role of soluble ferritin was related mainly to iron distribution between cells (Meyron-Holtz et al., 2011) . The observation that pharmacologic use of apoferritin, but not iron-loaded ferritin, establishes disease tolerance to sepsis (Figures 6G and 6I) argues that soluble ferritin also works as an iron chelator. This is in keeping with a previous report showing that ferritin administration in also protective against Escherichia coli infection in mice (Lipi nski et al., 1991) .
In conclusion, disease tolerance to sepsis relies on a crosstalk between host iron and glucose metabolic responses in which ferritin sustains liver glucose production to maintain blood glucose levels in response to infection within a dynamic range compatible with survival. These pathways can be targeted pharmacologically to promote the establishment of disease tolerance to systemic infections, possibly providing a novel therapeutic approach against sepsis.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENTS AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by, the Lead Contact, Miguel P. Soares (mpsoares@igc.gulbenkian.pt). Larsen et al., 2010) and confirmed in the liver by western blot ( Figure 1D) (Mutel et al., 2011) . Deletion of the G6pc1 lox/lox allele in Alb Cre ER T2 G6pc1 D/D mice was achieved by Tamoxifen administration (i.p.; 50mg/kg in 100 mL corn oil/5% ethanol for 5 consecutive days). Deletion was confirmed by western blot and genomic PCR of liver extracts ( Figure 5A ). All animal protocols used were approved by the Instituto Gulbenkian de Ciê ncia ethical committee and the ''Ó rga˜o Responsa´vel pelo Bem-estar dos Animais (ORBEA)'' and consequently licenced by the Direcca˜o Geral de Alimentaç a˜o e Veterina´ria (DGAV). All animal experiments follow the Portuguese (Portaria n 1005/92, Decreto-Lei n 113/2013) and European (Directive 2010/63/EU) legislations, concerning housing, husbandry and animal welfare.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cecal Ligation and Puncture CLP was performed essentially as described (Larsen et al., 2010) . Procedures were performed routinely at the same time frame, starting at 9 AM. CLP consisted of 20%-30% cecum ligation and double puncture with a 23 Gauge (G) needle. Severe CLP consisted of 60%-70% cecum ligation and double puncture with a 23 Gauge (G) needle. A small amount of faeces was extruded and the cecum was carefully placed back into the abdominal cavity. All animals received 0.9% saline (40 mL/kg, i.p.) and Imipenem/Cilastatin (25 mg/kg, i.p.), starting 2 hr after CLP and every 12 hr for 3 days). Survival was assessed twice daily for the first 3 days and once daily for a total of 14 days. Weight and temperature (Rodent Thermometer BIO-TK8851, Bioseb, France) were monitored daily for up to 7 days. Blood glucose levels (ACCU-CHECK Aviva, Roche, Amadora, Portugal) using tail vein blood was monitored in fed mice at several time points on the first day of analysis, twice daily on the second and then daily for up to 7 days. Alb- Cre 
ER
T2 G6pc1 D/D mice were subjected to CLP at least 3 weeks after the last Tamoxifen injection. Mx1
Cre Fth D/D mice were subjected to CLP 6-8 weeks after the first poly(I:C) administration.
Peritoneal Contamination and Infection PCI was induced as previously described (Gonnert et al., 2011) . Briefly, mice were injected i.p. with 2,2 ml/g body-weight of a human stool suspension. Body weight, blood glucose and disease severity were assessed twice daily. Disease severity was graded in five severity grads using a scoring system as described (Gonnert et al., 2011) : grade 1: no signs of disease; grade 2: mild disease; grade 3: medium severe disease; grade 4: severe disease, grade 5: death. Animals received 25 mg/g body weight Meropenem in 25 mL 0,9% NaCl/g body weight s.c., starting 12 hr after PCI, twice daily for a total of 6 injections. reconstitution was confirmed 4-6 weeks after bone marrow transfer by flow cytometry, assessing the relative proportion of peripheral blood leukocytes expressing the CD45.1/CD5.2 haplotypes and corresponding to cells derived from donor and recipient hematopoietic progenitors, respectively. Deletion of the Fth allele was achieved as described above. Mice were allowed to recover for up to 30 days after deletion before undergoing CLP. Deletion of the Fth lox/lox allele in bone marrow chimeras was achieved by Tamoxifen administration (gavage; 50mg/kg in 100 mL corn oil/5% ethanol for 5 consecutive days).
Bone Marrow Chimeras
Cell Lines
HepG2 cells were kindly provided from Robert Menard, Institut Pasteur, France.
METHOD DETAILS
In Vivo Recombinant Adenovirus (Rec.Ad.) The LacZ, FTH and FTH m Rec.Ad. were previously described Gozzelino et al., 2012 
Pathogen Load
Peritoneal fluid was obtained by peritoneal lavage (5 mL sterile PBS). Whole organs (i.e., spleen and liver) were harvested and homogenized under sterile conditions using a dounce tissue grinder . Heparanized blood was obtained by intracardial puncture. Serial dilutions were plated onto TrypticaseSoy Agar II with 5% Sheep Blood plates (Becton Dickinson Ref: 254053) and incubated (24 hr at 37 C) in air 5% CO 2 (aerobes) or in an air tight container equipped with the GasPak anaerobe container system (Becton Dickinson Ref 260678) . Anaerobic conditions were confirmed in all experiments using BBL Dry Anaerobic Indicator Strips (Becton Dickinson Ref: 271051) .
Histology
Mice were perfused in toto with ice cold PBS (10mL). Liver samples were harvested, fixed in 10% buffered formaldehyde for 48 hr at room temperature, then embedded in paraffin and stained with Hematoxylin & Eosin, essentially as described . prepared in blocking solution, overnight at 4 C. Slides were quickly washed with TBST and incubated with secondary antibodies (Alexa Fluorâ 568 Goat Anti-Rabbit and Alexa Fluorâ 647 Goat Anti-Rat, Life Technologies), prepared in blocking solution, for 2 hr at room temperature. Slides were washed first with TBST and then with PBS and mounted with Mowiol-Dabco containing 10mg/mL of DAPI. Images were acquired on a Leica DMRA2 upright microscope, equipped with a CoolSNAP HQ CCD camera, using a 40x HCX PL FLUOTAR objective, DAPI + TRITC + CY5 fluorescence filtersets, controlled with the MetaMorph V7.5.1/ software. The analysis was done with ImageJ (Rasband, W.S., ImageJ, U. S. NIH, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2014).
Heme Measurement
Total heme levels in the peritoneal cavity in C57BL/6 mice before or 3 hr after CLP were measured. Briefly, samples were diluted in H 2 O in 96 well plates and heme concentration was determined by comparison to a hemin standard curve (0.25-16 mM in H 2 O). Formic acid (150 mL/well; 98%-100%, Merck) was added and absorbance measured at 405nm using a microplate reader (Victor3 Multilabel Readers, Perkin Elmer).
qRT-PCR RNA was isolated from cells or livers using the NucleoSpin RNA kit (Macherey-Nagel). cDNA was transcribed from total RNA with transcriptor first strand cDNA synthesis kit (Roche (Ye et al., 2012) .
Western Blot
Proteins were extracted, electrophoresed, and electrotransferred essentially as described . Alternatively, for G6PC detection, samples were collected in HEPES-sucrose buffer/CHAPS and directly snap frozen. Total protein was quantified using Bradford assay. Anti-mouse G6PC1 (1:5000), anti-FTH1 (clone D1D4) (1:1000) (Cell Signaling), anti-p21 (1:1000) (2947, Cell Signaling), anti-b-actin (1:5000) (A5441, Sigma) and anti-a-tubulin-HRP (clone DM1A) (Sigma) (1:10000) were detected using peroxidase conjugated secondary antibodies (1 hr; room temperature) and developed with ECL western blotting substrate (ThermoFisher Scientific) for anti-b-tubulin and SuperSignal West Pico Chemiluminiscent substrate (ThermoFisher Scientific) for anti-G6PC and anti-FTH1 antibodies.
G6Pase Activity Livers from Fth lox/lox and Mx1
Cre Fth D/D mice without or 48 hr after being subjected to CLP were homogenized in liquid nitrogen and sonicated in HEPES-Sucrose (10 mM HEPES / 0.25 M Sucrose buffer). G6Pase enzymatic activity was determined essentially as described elsewhere (Mutel et al., 2011) . Absorption was measured using a Bio-Rad 3550-UV Reader at 700 nm. For G6Pase activity, HepG2 cells were collected 72h after Rec.Ad. transduction and when indicated 5 hr after heme and TNF treatment. Cells were collected in 10mM HEPES buffer, subjected to three cycles of freeze-thaw and G6Pase enzymatic activity was determined essentially as described elsewhere (Mutel et al., 2011) .
Cytokine Measurement
Cytokines were measured in serum 24 hr after CLP using Magpixâ Luminexâ (http://www.luminexcorp.com) according to manufacturer instructions.
Targeted Metabolomics
Targeted metabolomics for amino acid and glucose metabolism metabolites were determined by MetabolomicDiscoveries (Potsdam, Germany) using high-throughput Gas chromatography-mass spectrometry and accurate mass Quadrupole Time-of-Flight coupled to an Ultra Performance Liquid Chromatography.
Microarray Screening
Samples were processed by standard protocols: Briefly, RNA was extracted (RNeasy minikit; QIAGEN, Germany) and biotinylated probes were prepared using the TargetAmp-Nano Labeling Kit for Illuminaâ Expression. BeadChip. Illumina mouseRef8 V2 chips were scanned using the Illumina BeadArray Reader 500 X (Illumina). Arrays were read by GenomeStudio (v.1.9, and annotation MouseRef-8_V2_0_R3_11278551_A) yielding 25,697 bead types (probes) for each sample.
Metabolic Model Analysis
The metabolome data were analyzed in the context of an in silico metabolic model representation, using ratios between the 48 hr after CLP and 0 hr data points for every quantified metabolite. This was done independently for the metabolome datasets of both genotypes Fth lox/lox and Mx1 Cre Fth D/D . Ratios were integrated into the genome-scale metabolic model iMM1415 of Mus musculus (Sigurdsson et al., 2010) . Metabolic network reconstructions are concise representations of all stoichiometrically accurate metabolic reactions in a given organism. Reaction specific lower and upper thermodynamically feasible flux bounds were integrated if such information is available, otherwise were set to infinite. Of note, the exchange reaction subset comprises reactions that interchange metabolites with the environment or between different compartments within the model. If no exchange reaction existed for one of the measured metabolites a respective artificial exchange reaction was introduced into iMM1415 resulting in iMM1415*. In a first step, a flux variability analysis (FVA) (Mahadevan and Schilling, 2003) of iMM1415* with ATP exchange as objective function was performed. This provides the feasible flux boundaries of all model reactions, including exchange reactions, that allow for an optimal ATP yield as calculated by a flux balance analysis (FBA, 5% tolerance from optimal value accepted) (Orth et al., 2010 (Schellenberger et al., 2011) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Survival Plots were analyzed using the Log-rank test. Two-Way-ANOVA with a post hoc Bonferroni comparison and without for metabolomics was used when analyzing more than one group and time point. Mann-Whitney-U Test was used for pairwise comparisons. Analysis of microarray data were performed using R software version 3.02 (http://www.r-project.org/) and Bioconductor (Gentleman et al., 2004) packages. Raw data were subjected to robust spline normalization, quality control, and background correction with the R package Lumi (Du et al., 2008) . Transcripts with detection values p < 0.05 in at least four samples were called 'present' and taken for further analysis. Differentially expressed genes (DEG) were filtered according to microarray quality control criteria (Shi et al., 2006) by at least average two-fold changes and p values < 0.05 from Welch-modified t tests.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data files of the RNA Illumina screen reported in this paper are deposited in the GEO database (GEO: GSE92703), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92703. . Data are shown as mean ± SD from n = 4-5 mice per group, pooled from 3 independent experiments. (b) Serological markers of organ injury, before (Control; Ctr) and 12 hr after severe CLP C57BL/6 mice receiving apoferritin, ferritin, bovine serum albumin (BSA) or saline. Data are shown as mean ± SD from n = 4-5 mice per group, samples were pooled from 3 independent experiments. *p < 0.05, **p < 0.01; ****p < 0.001.
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